ArticleHuman molecular genetics2026
Neurodevelopmental alterations are key drivers of SPG56.
Article in Human molecular genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Biallelic pathological variants in CYP2U1 are associated with SPG56, a complex ultra-rare form of hereditary spastic paraplegia. CYP2U1 encodes a member of the cytochrome P450 family 2, which is highly expressed in the brain and involved in arachidonic acid metabolism and lipid hydroxylation. Little is known about the early stages of neurodevelopment in SPG56. To gain insight into the molecular mechanisms of the disease, we generated and characterized both a zebrafish knock-out model (cyp2u1-/-) and cortical neurons derived from induced pluripotent stem cells (iPSCs) of two patients affected by SPG56. cyp2u1-/- zebrafish showed increased mortality and locomotor impairment, and transcriptome analysis revealed defects in the cell cycle, neural development, and oxidative phosphorylation pathways, consistent with observed decreased cell proliferation, increased apoptosis, and bioenergetic impairment. To assess whether these molecular alterations impact network function, we performed local field potential recordings and whole-brain calcium imaging in mutant larvae. Local field potential analyses revealed prolonged high-frequency events despite reduced overall power, and calcium imaging showed increased skewness of neuronal activity distributions, findings indicating altered brain network dynamics in mutants. Transcriptional profiling of cortical cultures performed at neural progenitor, early-born, and mature neuron stages pointed to altered neural network development as one of the main pathogenic mechanisms of the disease and highlighted several similarities with the zebrafish model. Multiple features of the cyp2u1-/- zebrafish recall the human SPG56 phenotype, and combined transcriptomics profiling in cyp2u1-/- zebrafish and SPG56 patient iPSC-derived cortical neurons supports impaired neural network development as a key disease mechanism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.